Title |
Chemotherapy for metastatic and recurrent cervical cancer
|
---|---|
Published in |
Cochrane database of systematic reviews, October 2012
|
DOI | 10.1002/14651858.cd006469.pub2 |
Pubmed ID | |
Authors |
Kate Scatchard, Jennifer L Forrest, Maxine Flubacher, Paul Cornes, Chris Williams |
Abstract |
Cervical cancer is the second most common cancer among women up to 65 years of age and is the most frequent cause of death from gynaecological cancers worldwide. A woman's risk of developing cervical cancer by 65 years of age ranges from 0.69% in developed countries to 1.38% in developing countries. Although screening by Pap smear should mean early detection at a curable stage for most women, many still present with advanced or metastatic disease with a worse prognosis. The addition of platinum-based chemotherapy to radiotherapy has improved outcome compared to radiotherapy alone; however, 30% to 50% fail to respond to treatment or develop recurrent disease. There are no standard treatment options for these patients, although platinum-based chemotherapy is frequently used and trials are on-going. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Ecuador | 1 | <1% |
Belgium | 1 | <1% |
Unknown | 203 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 28 | 14% |
Researcher | 26 | 13% |
Student > Ph. D. Student | 20 | 10% |
Student > Bachelor | 18 | 9% |
Student > Postgraduate | 15 | 7% |
Other | 41 | 20% |
Unknown | 58 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 79 | 38% |
Nursing and Health Professions | 17 | 8% |
Biochemistry, Genetics and Molecular Biology | 15 | 7% |
Agricultural and Biological Sciences | 4 | 2% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
Other | 24 | 12% |
Unknown | 63 | 31% |